> top > docs > PMC:1283364 > spans > 2984-3196 > annotations

PMC:1283364 / 2984-3196 JSONTXT

Annnotations TAB JSON ListView MergeView

craft-sa-dev

Id Subject Object Predicate Lexical cue
T845 0-212 sentence denotes Early evidence from clinical trials of antibody-mediated clearance, one of the first Aβ-lowering approaches tested in humans, suggested that treatments designed to reduce amyloid burden may indeed be beneficial.
T846 1-6 JJ denotes Early
T847 7-15 NN denotes evidence
T848 127-136 VBD denotes suggested
T849 16-20 IN denotes from
T850 21-29 JJ denotes clinical
T851 30-36 NNS denotes trials
T852 37-39 IN denotes of
T853 40-48 NN denotes antibody
T854 49-57 VBN denotes mediated
T855 48-49 HYPH denotes -
T856 58-67 NN denotes clearance
T857 67-69 , denotes ,
T858 69-72 CD denotes one
T859 73-75 IN denotes of
T860 76-79 DT denotes the
T861 98-108 NNS denotes approaches
T862 80-85 JJ denotes first
T863 86-88 NN denotes Aβ
T864 89-97 VBG denotes lowering
T865 88-89 HYPH denotes -
T866 109-115 VBN denotes tested
T867 116-118 IN denotes in
T868 119-125 NNS denotes humans
T869 125-127 , denotes ,
T870 137-141 IN denotes that
T871 198-200 VB denotes be
T872 142-152 NNS denotes treatments
T873 153-161 VBN denotes designed
T874 162-164 TO denotes to
T875 165-171 VB denotes reduce
T876 172-179 NN denotes amyloid
T877 180-186 NN denotes burden
T878 187-190 MD denotes may
T879 191-197 RB denotes indeed
T880 201-211 JJ denotes beneficial
T881 211-212 . denotes .
R457 T846 T847 amod Early,evidence
R458 T847 T848 nsubj evidence,suggested
R459 T849 T847 prep from,evidence
R460 T850 T851 amod clinical,trials
R461 T851 T849 pobj trials,from
R462 T852 T851 prep of,trials
R463 T853 T854 npadvmod antibody,mediated
R464 T854 T856 amod mediated,clearance
R465 T855 T854 punct -,mediated
R466 T856 T852 pobj clearance,of
R467 T857 T856 punct ", ",clearance
R468 T858 T856 appos one,clearance
R469 T859 T858 prep of,one
R470 T860 T861 det the,approaches
R472 T862 T861 amod first,approaches
R473 T863 T864 npadvmod Aβ,lowering
R474 T864 T861 amod lowering,approaches
R475 T865 T864 punct -,lowering
R476 T866 T861 acl tested,approaches
R477 T867 T866 prep in,tested
R478 T868 T867 pobj humans,in
R479 T869 T848 punct ", ",suggested
R480 T870 T871 mark that,be
R481 T871 T848 ccomp be,suggested
R482 T872 T871 nsubj treatments,be
R483 T873 T872 acl designed,treatments
R484 T874 T875 aux to,reduce
R485 T875 T873 advcl reduce,designed
R486 T876 T877 compound amyloid,burden
R487 T877 T875 dobj burden,reduce
R488 T878 T871 aux may,be
R489 T879 T871 advmod indeed,be
R490 T880 T871 acomp beneficial,be
R491 T881 T848 punct .,suggested
R471 T861 T859 pobj approaches,of

craft-ca-core-ex-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue
T634 40-48 GO:0042571 denotes antibody
T635 86-88 CHEBI_PR_EXT:amyloid_beta denotes Aβ
T636 119-125 NCBITaxon:9606 denotes humans
T637 172-179 CHEBI:60425 denotes amyloid

craft-ca-core-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue
T559 40-48 GO:0042571 denotes antibody
T560 119-125 NCBITaxon:9606 denotes humans
T561 172-179 CHEBI:60425 denotes amyloid